Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report)‘s stock had its “outperform” rating restated by Wedbush in a report issued on Monday, RTT News reports. They currently have a $18.00 target price on the stock, up from their previous target price of $12.00. Wedbush’s price objective would indicate a potential upside of 25.35% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Y-mAbs Therapeutics in a research note on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $12.50.

View Our Latest Analysis on YMAB

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB traded up $1.25 on Monday, reaching $14.36. The company’s stock had a trading volume of 823,528 shares, compared to its average volume of 453,380. The stock has a market cap of $626.41 million, a PE ratio of -32.64 and a beta of 0.69. Y-mAbs Therapeutics has a twelve month low of $2.70 and a twelve month high of $14.49. The firm’s 50 day moving average is $8.76 and its two-hundred day moving average is $6.61.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 20.75% and a negative return on equity of 18.28%. The company had revenue of $20.45 million during the quarter, compared to the consensus estimate of $20.56 million. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $6.61, for a total transaction of $330,500.00. Following the completion of the sale, the insider now owns 265,032 shares in the company, valued at $1,751,861.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Johan Wedell-Wedellsborg bought 62,516 shares of the company’s stock in a transaction on Monday, November 27th. The shares were purchased at an average price of $5.49 per share, with a total value of $343,212.84. Following the transaction, the director now directly owns 4,342,721 shares in the company, valued at $23,841,538.29. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas Gad sold 50,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $6.61, for a total transaction of $330,500.00. Following the completion of the transaction, the insider now directly owns 265,032 shares in the company, valued at $1,751,861.52. The disclosure for this sale can be found here. In the last three months, insiders have acquired 223,399 shares of company stock worth $1,413,939 and have sold 175,000 shares worth $1,057,000. Company insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in YMAB. China Universal Asset Management Co. Ltd. bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $34,000. Tower Research Capital LLC TRC grew its stake in Y-mAbs Therapeutics by 924.1% during the first quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock valued at $30,000 after acquiring an additional 5,323 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Y-mAbs Therapeutics by 248.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,513 shares of the company’s stock worth $99,000 after acquiring an additional 4,645 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Y-mAbs Therapeutics by 172.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock worth $121,000 after purchasing an additional 5,052 shares in the last quarter. Finally, Avestar Capital LLC purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $68,000. Institutional investors own 45.45% of the company’s stock.

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

See Also

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.